Metabolic disorders and steatosis in patients with chronic hepatitis C: metabolic strategies for antiviral treatments.

about

Metabolic alterations and hepatitis C: From bench to bedside The hepatic cannabinoid 1 receptor as a modulator of hepatic energy state and food intake Hepatitis C virus, cholesterol and lipoproteins--impact for the viral life cycle and pathogenesis of liver disease.

P2860

Q26773261-E4EFCB35-95C0-4933-A0DF-FFB515E23C66 Q26850858-BB359F62-038D-4E80-A06E-FEC6BB0C1CCE Q37015738-A29319D2-810A-4315-B60D-41DC91664C9A

P2860

Metabolic disorders and steatosis in patients with chronic hepatitis C: metabolic strategies for antiviral treatments.

Item

http://www.wikidata.org/entity/Q36026554

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

2012年论文

@zh

2012年论文

@zh-cn

name

Metabolic disorders and steato ...... gies for antiviral treatments.

@ast

Metabolic disorders and steato ...... gies for antiviral treatments.

@en

type

Item

label

Metabolic disorders and steato ...... gies for antiviral treatments.

@ast

Metabolic disorders and steato ...... gies for antiviral treatments.

@en

prefLabel

Metabolic disorders and steato ...... gies for antiviral treatments.

@ast

Metabolic disorders and steato ...... gies for antiviral treatments.

@en

P1476

Metabolic disorders and steato ...... gies for antiviral treatments.

@en

P2093

Kazuhiro Kotoh

http://www.w3.org/2001/XMLSchema#string

Makoto Nakamuta

http://www.w3.org/2001/XMLSchema#string

Motoyuki Kohjima

http://www.w3.org/2001/XMLSchema#string

Munechika Enjoji

http://www.w3.org/2001/XMLSchema#string

P2860

Identification of FBL2 as a geranylgeranylated cellular protein required for hepatitis C virus RNA replication

Endocannabinoid activation at hepatic CB1 receptors stimulates fatty acid synthesis and contributes to diet-induced obesity

The endocannabinoid system as an emerging target of pharmacotherapy

Hepatitis C virus hijacks host lipid metabolism

Hepatitis C Virus Down-Regulates Insulin Receptor Substrates 1 and 2 through Up-Regulation of Suppressor of Cytokine Signaling 3

Inhibition of hepatitis C virus replication by peroxidation of arachidonate and restoration by vitamin E

SOCS-1 and SOCS-3 block insulin signaling by ubiquitin-mediated degradation of IRS1 and IRS2

Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance

Suppressor of cytokine signaling 1 (SOCS-1) and SOCS-3 cause insulin resistance through inhibition of tyrosine phosphorylation of insulin receptor substrate proteins by discrete mechanisms

IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy

P304

264017

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1155/2012/264017

http://www.w3.org/2001/XMLSchema#string

P478

2012

http://www.w3.org/2001/XMLSchema#string

P577

2012-06-04T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

225375959

http://www.w3.org/2001/XMLSchema#string

P698

22701799

http://www.w3.org/2001/XMLSchema#string

P932

3373124

http://www.w3.org/2001/XMLSchema#string

Metabolic disorders and steatosis in patients with chronic hepatitis C: metabolic strategies for antiviral treatments.

about

P2860

P2860

Metabolic disorders and steatosis in patients with chronic hepatitis C: metabolic strategies for antiviral treatments.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P478

P577

P5875

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P478

P577

P5875

P698

P932